Duchenne: who remains outside the options at $CAPR, $SRPT, $RGNX and $DYN?

01. The Patient Missing From the Headline

A headline about a Duchenne therapy can sound as though it applies to everyone with the disease. The actual evidence may concern a particular mutation, a specific age range, patients who can still walk, or people who meet a safety and antibody profile. Those details determine who is inside the evidence and who remains outside it.

This is the most useful way to compare Capricor, Sarepta, REGENXBIO and Dyne. The companies are not simply pursuing four versions of the same product for the same population. Their approaches differ, and so do the boundaries around their current evidence and regulatory status.

The distinction has a human and an economic consequence. An outcome that matters greatly to a person who no longer walks may be poorly represented by a walking test. Conversely, a product’s relevance to the disease in general does not establish its suitability for every person living with it. A market estimate that ignores those distinctions can become detached from both medicine and the actual label.

The question here is therefore not “Which company wins Duchenne?” It is: which patients does the evidence describe, which function does it measure, and what remains unavailable or unproven for everybody else?

02. Four Boundaries That Must Stay Separate

First comes biological fit. A mutation-specific exon-skipping candidate addresses a defined genetic subset. A different strategy may not use the same mutation boundary, but that does not make it unrestricted.

Second comes study eligibility. A trial’s age range, functional criteria and exclusions determine who contributed to its results. These are research criteria, not a promise that a future label will include every enrolled category or extend to people who were not studied.

Third comes regulatory authorization. An approved label specifies an authorized population and conditions of use. A submitted application describes what a company is asking the regulator to consider. The latter is not the former.

Fourth comes practical and clinical suitability. A person can appear to fit a broad age or mutation description while requiring further assessment of safety, organ function, immune status or the treatment process. This article is not an eligibility screening tool; these decisions belong with specialist teams.

Keeping the four boundaries separate prevents a misleading subtraction exercise. People excluded from one treatment are not automatically the addressable population for another. There can be overlap, gaps and unanswered questions that cannot be resolved by adding corporate presentations together.

03. Sarepta: Read Today’s ELEVIDYS Label, Not an Older One

The current FDA-hosted ELEVIDYS label specifies patients aged four years and older with Duchenne who are ambulatory and have a confirmed DMD mutation. It also requires selection based on anti-AAVrh74 antibody testing and includes a contraindication for deletions involving any portion of exon 8 and/or exon 9. These are not minor footnotes to an otherwise universal indication. FDA prescribing information.

The label carries a boxed warning for acute serious liver injury and acute liver failure, including fatal outcomes. The FDA’s November 2025 announcement explained the revised indication restricting use to ambulatory patients following reports of fatal liver failure. An older account that includes nonambulatory patients as part of the current authorized population is therefore not an acceptable basis for this comparison. FDA safety and indication announcement.

This is not a statement that everyone excluded by the current label has the same clinical circumstances. It is a statement about the authorized population. Nor does remaining inside the label remove the need to weigh serious risks and monitor appropriately.

The investing implication is analytical rather than predictive: the relevant population cannot be derived from the total prevalence of Duchenne alone. Age and walking ability are only the first filters visible in the indication. A model also has to respect the other conditions that govern use, rather than treating them as optional reductions applied after a market-size headline has been selected.

The Sarepta Therapeutics Stock Hub provides the wider company context. This section concerns the current ELEVIDYS boundary, not a conclusion about every product or program in Sarepta’s portfolio.

04. Dyne: Better Delivery Does Not Remove the Mutation Boundary

Dyne’s zeleciment rostudirsen, also called z-rostudirsen or DYNE-251, is directed at Duchenne amenable to exon 51 skipping. In July, the company announced FDA acceptance of its BLA for review, with a January 21, 2027 target action date. The application seeks accelerated approval based on dystrophin as a surrogate endpoint. The candidate remains investigational at this article’s cutoff. Dyne’s BLA announcement.

The mutation boundary matters independently of the delivery technology. A platform intended to improve delivery does not make one exon-specific product applicable to every DMD mutation. Other exon programs represent separate development work, not an expansion of the existing candidate by implication.

Dystrophin evidence and functional evidence must also remain distinct. A biological measurement can support a development or regulatory proposition while leaving important questions about the magnitude and durability of functional benefit. That is why the nature of the approval pathway and the confirmatory evidence matter alongside the amount of protein reported.

The application announcement does not establish a final FDA-approved age range, ambulatory-status rule or full safety label. It would be premature to fill those boxes using a trial description or a commercial launch expectation. Those elements become authoritative when the relevant regulatory decision and labeling exist.

For the Dyne Therapeutics Stock Hub, the company-level question includes the wider platform and its financing. For this article, the narrower question is whether a defined genetic subgroup can receive a demonstrated functional benefit with an acceptable treatment burden. More efficient delivery is part of that proposition, not a substitute for proving it.

05. REGENXBIO: Protein Expression Is Not the Whole Functional Story

RGX-202 is an investigational microdystrophin gene-therapy program. REGENXBIO’s June announcement reported completion of dosing in its confirmatory study and described a planned safety package for a potential BLA. The announcement contained biomarker results and early functional observations, but those observations did not provide the same duration of follow-up for every patient in the planned submission package. June 24 program update.

This is an important denominator problem. A safety population, a biopsy population and a group with mature functional follow-up are different populations unless the source explicitly shows otherwise. Quoting the largest enrollment number next to the most mature functional result can leave readers with the false impression that everybody has reached the same milestone.

The program’s patient materials discuss research in young children, but a trial’s inclusion of a younger age group does not create an approved indication for that group. An investigational program can broaden the questions being studied without yet broadening the options available through an approved product. REGENXBIO’s Duchenne program.

REGENXBIO’s August update reiterated a target to initiate the RGX-202 BLA submission in Q3 2026. By the October 9 cutoff used here, that quarter had ended; this article did not verify a completed initiation or submission. The appropriate wording is therefore a dated company target whose completion was not established, not “filed” or “under FDA review.” Q2 2026 update.

The REGENXBIO Stock Hub covers the broader portfolio. Events affecting a different REGENXBIO candidate should not be imported into RGX-202 without a source establishing that connection.

06. Capricor: Upper-Limb Function Is a Distinct Question

Capricor’s deramiocel is not an exon-skipping product or a microdystrophin gene therapy. Its clinical program asks a different question about preserving function. The company’s August regulatory update described a major amendment and a refined proposed indication focused on upper-limb function, with the FDA target date extended to November 22, 2026. It should not be described as an approved Duchenne therapy or as an established cardiomyopathy indication. August 24 regulatory update.

For people who no longer walk, upper-limb function is not a secondary version of the same walking endpoint. It concerns a different set of abilities. The analytical value of this program is that it forces the comparison to consider which function a study is trying to preserve, rather than treating ambulation as the only outcome worth discussing.

However, medical relevance does not settle statistical or regulatory uncertainty. FDA briefing materials for the July advisory discussion raised concerns about the analysis of the randomized evidence, including the relationship between prespecified methods and subsequent analyses. Those concerns cannot be erased by using the company’s description of the trial as a definitive regulatory conclusion. Briefing materials are staff assessments, not the agency’s final decision. FDA briefing document.

Capricor’s October 5 open-label extension update reported 76% slower decline in the crossover group during its treatment year compared with that same group’s preceding placebo year. That was not a 76% advantage over a concurrent randomized placebo group. The company stated that the 24-month comparisons had no allocated statistical alpha and were not powered for those comparisons. HOPE-3 extension update.

A within-person comparison over successive periods can be informative, but it does not recreate the protections of a concurrent blinded comparison. Changes over time, follow-up availability and the structure of the extension all affect interpretation. The appropriate conclusion is that the extension adds evidence to evaluate, not that it independently resolves every concern raised about the pivotal analysis.

The Capricor Therapeutics Stock Hub supplies the full company background. The central question here remains whether the proposed functional benefit is convincingly established for the population and indication being requested.

07. Three Illustrative Patients, Not Three Treatment Recommendations

Consider a hypothetical young child with a mutation that is not amenable to exon 51 skipping. A positive result for DYNE-251 would not, by itself, create an option for that child’s mutation. Another company’s broader mechanistic strategy might be relevant to research, but the actual label or trial criteria would still have to be checked.

Now consider an older person who no longer walks but retains useful arm and hand function. An ambulatory-only label does not include that person simply because the underlying disease is the same. A study measuring preservation of upper-limb function may ask a more relevant question, but relevance alone does not establish approval or individual eligibility.

Finally, consider someone who appears to fit an age and walking-ability description but has a safety factor that complicates treatment. A broad demographic match cannot replace specialist assessment of the full label and the individual’s clinical circumstances. This is why a short market presentation cannot function as a treatment-selection guide.

These examples are deliberately hypothetical. They illustrate why the eligible population is an intersection of conditions, not a single headline number. They also explain why a new development success can be important without solving the unmet need for everybody with Duchenne.

08. Do Not Add the Populations Together

The four programs cannot be assigned nonoverlapping slices of a single market simply because they use different mechanisms. Some people may fall within more than one program’s research scope. Others may fall outside all current options under discussion. Some boundaries may change with future evidence, while others remain fundamental to the mechanism.

Likewise, complementary biological ideas do not establish a proven combination regimen. The fact that one approach concerns protein production and another concerns preservation of function does not demonstrate that using them together is safe or produces additional benefit. That claim would require evidence beyond the four-company comparison.

For financial analysis, the disciplined sequence begins with the actual authorized or proposed population, then considers clinical suitability, access, treatment delivery and persistence where relevant. Only after those steps does a revenue model become more than a multiplication of prevalence by an assumed price.

There is also a time distinction. A population addressed by a current approval is not economically equivalent to a population that might be addressed after future studies and regulatory decisions. Assigning both the same probability and start date would hide development risk inside the arithmetic.

09. What Would Change the Comparison?

For Sarepta, a change in the authoritative label or a material safety update would alter the current eligibility discussion. For Dyne, the FDA’s decision and any resulting label would replace assumptions about the final population with an actual regulatory answer. For REGENXBIO, a verified filing milestone and more mature functional evidence would clarify both timing and the strength of the submission package.

For Capricor, the regulatory assessment of the amended application matters alongside the extension data. The question is not whether preserving arm function is important. It is whether the evidence supports the particular benefit and population being proposed under the agency’s standards.

The most useful next update is therefore not necessarily the largest protein percentage or the broadest market estimate. It is the update that changes the answer to a concrete question: who can receive the treatment, what function it has been shown to preserve, and what risks or uncertainties remain?

That framework gives all four companies room to be judged on their own evidence. It also keeps visible the people who remain outside the current boundaries, rather than allowing them to disappear behind a disease-wide opportunity figure.

Sources and Scope

Research cutoff: October 9, 2026. Current FDA materials control descriptions of approved use. Company releases support attributed trial updates and guidance; they do not establish an FDA conclusion. Illustrative patient scenarios are analytical examples, not clinical advice or determinations of eligibility.

Company research: CAPR, SRPT, RGNX and DYN. All four links lead to the existing central company hubs.